EcoDrugPlus

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSBTAG00000000648
Gene Symbol: ADAMTS5
6 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSBTAG00000003058
Gene Symbol: ADRM1
5 Enzyme and pathways 5 Cross references
272 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSBTAG00000017636
Gene Symbol: AKT1
5 Cross references
231 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSBTAG00000001400
Gene Symbol: AKT2
15 Enzyme and pathways 5 Cross references
269 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSBTAG00000017788
Gene Symbol: AKT3
5 Cross references
213 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSBTAG00000007379
Gene Symbol: ALK
3 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSBTAG00000021090
Gene Symbol: ABCC1
19 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSBTAG00000000983
Gene Symbol: ABCC8
7 Enzyme and pathways 5 Cross references
260 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSBTAG00000019294
Gene Symbol: ABCC9
9 Enzyme and pathways 5 Cross references
244 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSBTAG00000008777
Gene Symbol: ATP4A
3 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSBTAG00000019961
Gene Symbol: ATP4B
3 Enzyme and pathways 5 Cross references
183 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSBTAG00000001246
Gene Symbol: ATP1A1
6 Enzyme and pathways 5 Cross references
341 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).